Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions

Abstract

The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.

1 . A compound having the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or prodrug thereof, wherein
 a is an integer of 1 to 3; 
 b is an integer of 0 to 4, wherein when b is 0, the carbon bonded to X and W is not bonded to 2 or more heteroatoms; 
 each of R′, R 2 , and R 3  is, independently, H or C 1-6  alkyl; 
 R 4  is H, optionally substituted C 1-6  alkyl, optionally substituted C 7-16  aralkyl, or optionally substituted C 2-15  heterocyclylalkyl; 
 R 5  is CO 2 H, SO 3 H, OSO 3 H, OP(O)(OH) 2 , or 5-tetrazolyl; 
 X is selected from the group consisting of —NR X1 V, —N(R X1 )C(O)V, —N(R X1 )C(S)V, —N(R X1 )C(O)N(R X2 )V, —N(R X1 )C(S)N(R X2 )V, —N(R X1 )C(O)OV, —N(R X1 )S(O) 2 V, —C(O)N(R X1 )V, —C(O)OV, —OC(O)V, —OC(O)OV, and —OC(O)N(R X1 )V, where each of R X1  and R X2  is, independently, H or C 1-6  alkyl, and V is a C 1-20  alkyl, C 1-20  alkenyl, or C 1-20  alkynyl group, optionally substituted with halo, hydroxyl, C 1-21  acyloxy, oxo, C 1-20  alkoxyl, or C 1-20  thioalkoxyl and optionally containing 1 or 2 phenyl or biphenyl moieties in and/or at the end of the carbon chain; 
 W is selected from the group consisting of H, —C(O)N(R W1 )R W2 , —C(O)OR W2 , —(CH 2 ) c OR W3 , —(CH 2 ) c SR W3 , —(CH 2 ) c O(CH 2 ) d CH(OR W3 )R W4 , —(CH 2 ) c S(CH 2 ) d CH(OR W3 )R W4 , —C(O)N(R W1 )(CH 2 ) c CH(OR W3 )R W4 , and —C(O)N(R W1 )(CH 2 ) c CH(OR W3 )(CH 2 ) e OR W5 , wherein each of c and d is, independently, an integer of 1 to 4, e is an integer of 2 to 4, R W1  is H or C 1-6  alkyl, R W2  is C 1-20  alkyl, C 1-20  alkenyl, or C 1-20  alkynyl, each of R W3  and R W5  is, independently, H, C 1-20  alkyl, C 1-21  acyl, C 1-20  alkenyl, or C 1-20  alkynyl, and R W4  is H, C 1-20  alkyl, C 1-20  alkenyl, or C 1-20  alkynyl, wherein each of R W2 , R W3 , R W4 , and R W5  is optionally substituted with halo, hydroxyl, C 1-21  acyloxy, oxo, C 1-20  alkoxyl, or C 1-20  thioalkoxyl, optionally contains 1 to 2 phenyl or biphenyl moieties in and/or at the end of the carbon chain, and optionally contains 1 to 4 non-vicinal oxygen atoms in the carbon chain; and 
 U is selected from the group consisting of 
 
       
         
           
           
               
               
           
         
       
       wherein
 f is an integer of 1 to 4, g is 0 or 1, 
 each of R U1 , R U2 , and R U3  is, independently, H, optionally substituted C 1-6  alkyl, optionally substituted C 7-16  aralkyl, or optionally substituted C 2-15  heterocyclylalkyl; or R U1  is H or optionally substituted C 1-6  alkyl, and R U2  and R U3  together with the carbon atom they are bonded to form an optionally substituted C 3-6  aliphatic ring; or R U2  is H, and R U3  and R U1  together with the carbon atom bonded to R U3  and the nitrogen atom bonded to R U1  form an optionally substituted 4-6-membered heterocyclic ring, 
 R U4  is selected from the group consisting of —CH 2 R U5 , —C(O)R U6 , —C(O)NH(R U7 ), and —C(O)O(R U8 ), wherein each of R U5 , R 6 , R U7 , and R U8  is selected from the group consisting of optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted C 2-6  alkynyl, optionally substituted C 7-16  aralkyl, optionally substituted C 2-15  heterocyclylalkyl, optionally substituted C 6-10  aryl, and optionally substituted C 1-9  heterocyclyl, or R U4  is a peptide chain of 1 to 10 natural or non-natural amino acids, or mixture thereof, linked via the C-terminal end and substituted at the N-terminal end of the peptide with a group selected from H, —CH 2 R U5 , —C(O)R U6 , —C(O)NH(R U7 ), and —C(O)O(R U8 ), wherein each of R U5 , R U6 , R U7 , and R U8  is as defined above, and 
 R U5a  is a peptide chain of 1 to 10 natural or non-natural amino acids, or mixture thereof, linked via the N-terminal end and the C-terminal end is CO 2 R U9 , or CONR U10 R 11 , wherein each of R U9 , R U10 , and R U11  is selected from the group consisting of H, optionally substituted C 1-6  alkyl, optionally substituted C 2-6  alkenyl, optionally substituted C 2-6  alkynyl, optionally substituted C 7-16  aralkyl, optionally substituted C 2-15  heterocyclylalkyl, optionally substituted C 6-10  aryl, and optionally substituted C 1-9  heterocyclyl. 
 
     
     
         2 . The compound of  claim 1 , wherein X or W contains at least one linear alkyl moiety of 7 or more carbons. 
     
     
         3 . The compound of  claim 1 , wherein each of X and W contain at least one linear alkyl moiety of 7 or more carbons. 
     
     
         4 . The compound of  claim 1 , wherein W is —C(O)NH(CH 2 ) 2 CH(OH)R W4 , wherein R W4  is C 7-19  alkyl. 
     
     
         5 . The compound of  claim 1 , wherein W is —C(O)NH(CH 2 ) 2 CH 2 OR W3 , wherein R W3  is —C(O)(CH 2 ) aa CH 3 , wherein aa is an integer of 6 to 18. 
     
     
         6 . The compound of  claim 1 , wherein W is —C(O)NH(CH 2 ) 2 CH(OR W3 )R W4 , wherein R W3  is —C(O)(CH 2 ) aa CH 3 , and R W4  is —CH 2 OC(O)(CH 2 ) bb CH 3 , wherein each of aa and bb is, independently, an integer of 6 to 18. 
     
     
         7 . The compound of  claim 1 , wherein U is —C(O)C(R U2 )(R U3 )NHR U4  or —C(O)(CH 2 ) f NHR U4 , R U2  is an optionally substituted C 1-6  alkyl, R U3  is H, and R U4  is an optionally substituted C 6-10  aryl or an optionally substituted C 2-9  heteroaryl. 
     
     
         8 . The compound of  claim 1 , wherein U is 
       
         
           
           
               
               
           
         
       
       wherein
 R U2  is C 1-6  alkyl, R U3  is H, and R 12  is H, optionally substituted C 6-10  aryl, optionally substituted C 6-10  aryloxy, optionally substituted C 7-16  aralkyl, optionally substituted C 7-16  aralkoxy, optionally substituted C 2-9  heterocyclyl, optionally substituted C 2-9  heterocyclyloxy, optionally substituted C 3-15  heterocyclylalkyl, or optionally substituted C 3-15  heterocyclylalkyloxy. 
 
     
     
         9 . The compound of  claim 8 , wherein U is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
     
     
         10 . The compound of  claim 1 , wherein said compounds is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The compound of  claim 1 , wherein said compounds is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         12 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically acceptable excipient.